The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Effect of tirzepatide on the risk of diabetic retinopathy in type 2 diabetes
Open accessAbstract
None to declare. The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.15535. The data generated in this research will be shared on reasonable request to the correspondingauthor. Data S1. Supporting Information. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A meta-analysis of the SURPASS program RCT showed a neutral effect of TZP on diabetic retinopathy, although an exiguous number of events occurred and high risk patients were excluded from these trials.
“A meta-analysis of the SURPASS program RCT showed a neutral effect of TZP on diabetic retinopathy, although an exiguous number of events occurred and high risk patients were excluded from these trials [28].”
From The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database (2024) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s009 · Cited by 662
Nauck, M. A., & D‘Alessio, D. A. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01604-7 · Cited by 407
Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review
Bain, S. C., Klufas, M. A., Ho, A. C., & Matthews, D. R. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13538 · Cited by 306
Wang, F., Mao, Y., Wang, H., Liu, Y., & Huang, P. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01110-w · Cited by 73
Permana, H., Yanto, T. A., & Hariyanto, T. I. (2022) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102640 · Cited by 38
Should tirzepatide be considered for early management in type 2 diabetes? Pros and cons
Koufakis, T., Popovic, D. S., & Παπάνας, Ν. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2237414 · Cited by 10
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Caruso, I., Di Gioia, L., Di Molfetta, S., Caporusso, M., Cignarelli, A., Sorice, G. P., Laviola, L., & Giorgino, F. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02441-z · Cited by 49
Metadata
- Authors
- Popovic, D. S., Patoulias, D., Karakasis, P., Koufakis, T., & Papanas, N.
- Affiliations
- University of Novi Sad (RS)
- Aristotle University of Thessaloniki (GR)
- Diabetes Centre, Second Department of Internal Medicine Democritus University of Thrace, University Hospital of Alexandroupolis Alexandroupoli Greece
- Corresponding author
- Popovic, Djordje S.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2024-03-08
- Volume
- 26
- Issue
- 6
- Pages
- 2497-2500
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W4392589483
- Cited by
- 21
- References
- 7
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 7
- FWCI
- 8.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Obesity and Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- tirzepatide, diabetic retinopathy, type 2 diabetes, retinopathy risk, GLP-1 receptor agonists
- MeSH terms
- Aged, Diabetes Mellitus, Type 2, Diabetic Retinopathy, Female, Humans, Hypoglycemic Agents, Male, Middle Aged
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
